U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C25H28N6O
Molecular Weight 428.5304
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of IRBESARTAN

SMILES

CCCCC1=NC2(CCCC2)C(=O)N1Cc3ccc(cc3)-c4ccccc4-c5n[nH]nn5

InChI

InChIKey=YOSHYTLCDANDAN-UHFFFAOYSA-N
InChI=1S/C25H28N6O/c1-2-3-10-22-26-25(15-6-7-16-25)24(32)31(22)17-18-11-13-19(14-12-18)20-8-4-5-9-21(20)23-27-29-30-28-23/h4-5,8-9,11-14H,2-3,6-7,10,15-17H2,1H3,(H,27,28,29,30)

HIDE SMILES / InChI
(more than 8500-fold) for the AT1 receptor than for the AT2 receptor and no agonist activity.

CNS Activity

Curator's Comment:: Studies in animals indicate that radiolabeled irbesartan weakly crosses the blood-brain barrier and placenta.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
AVAPRO

Approved Use

AVAPRO is an angiotensin II receptor blocker (ARB) indicated for: • Treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. (1.1) • Treatment of diabetic nephropathy in hypertensive patients with type 2 diabetes, an elevated serum creatinine, and proteinuria

Launch Date

875577600000
Primary
AVAPRO

Approved Use

AVAPRO is an angiotensin II receptor blocker (ARB) indicated for: • Treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. (1.1) • Treatment of diabetic nephropathy in hypertensive patients with type 2 diabetes, an elevated serum creatinine, and proteinuria

Launch Date

875577600000
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
3.3 μg/mL
300 mg 1 times / day multiple, oral
dose: 300 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
IRBESARTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
2.9 μg/mL
300 mg single, oral
dose: 300 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
IRBESARTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
4.4 μg/mL
600 mg 1 times / day multiple, oral
dose: 600 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
IRBESARTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
4.9 μg/mL
600 mg single, oral
dose: 600 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
IRBESARTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
5.6 μg/mL
900 mg 1 times / day multiple, oral
dose: 900 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
IRBESARTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
5.3 μg/mL
900 mg single, oral
dose: 900 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
IRBESARTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
2.04 μg/mL
150 mg 1 times / day multiple, oral
dose: 150 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
IRBESARTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
1.9 μg/mL
150 mg single, oral
dose: 150 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
IRBESARTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
19.8 μg × h/mL
300 mg 1 times / day multiple, oral
dose: 300 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
IRBESARTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
20 μg × h/mL
300 mg single, oral
dose: 300 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
IRBESARTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
31.9 μg × h/mL
600 mg 1 times / day multiple, oral
dose: 600 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
IRBESARTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
32.6 μg × h/mL
600 mg single, oral
dose: 600 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
IRBESARTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
34.2 μg × h/mL
900 mg 1 times / day multiple, oral
dose: 900 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
IRBESARTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
44.8 μg × h/mL
900 mg single, oral
dose: 900 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
IRBESARTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
9.3 μg × h/mL
150 mg 1 times / day multiple, oral
dose: 150 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
IRBESARTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
9.7 μg × h/mL
150 mg single, oral
dose: 150 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
IRBESARTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
11 h
300 mg 1 times / day multiple, oral
dose: 300 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
IRBESARTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
14 h
300 mg single, oral
dose: 300 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
IRBESARTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
15 h
600 mg 1 times / day multiple, oral
dose: 600 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
IRBESARTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
14 h
600 mg single, oral
dose: 600 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
IRBESARTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
14 h
900 mg 1 times / day multiple, oral
dose: 900 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
IRBESARTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
17 h
900 mg single, oral
dose: 900 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
IRBESARTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
11 h
150 mg 1 times / day multiple, oral
dose: 150 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
IRBESARTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
16 h
150 mg single, oral
dose: 150 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
IRBESARTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
10%
unknown, unknown
IRBESARTAN serum
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
900 mg 1 times / day multiple, oral
Highest studied dose
Dose: 900 mg, 1 times / day
Route: oral
Route: multiple
Dose: 900 mg, 1 times / day
Sources:
healthy, 20-45
Health Status: healthy
Age Group: 20-45
Sex: M+F
Sources:
300 mg 1 times / day multiple, oral
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
unhealthy
Disc. AE: Hyperkalemia...
AEs leading to
discontinuation/dose reduction:
Hyperkalemia (2.1%)
Sources:
300 mg 1 times / day multiple, oral
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
unhealthy
Disc. AE: Disorder fetal...
AEs leading to
discontinuation/dose reduction:
Disorder fetal
Sources:
AEs

AEs

AESignificanceDosePopulation
Hyperkalemia 2.1%
Disc. AE
300 mg 1 times / day multiple, oral
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
unhealthy
Disorder fetal Disc. AE
300 mg 1 times / day multiple, oral
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
unhealthy
Overview

OverviewOther

Drug as perpetrator​Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
yes
yes
yes (co-administration study)
Comment: in clinical studies the consequences of concomitant irbesartan on the pharmacodynamics of warfarin were negligible
Page: 12
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
PubMed

PubMed

TitleDatePubMed
Pharmacology of AT1-receptor blockers.
2001
The relationship between dose and antihypertensive effect for different AT1-receptor blockers.
2001
Clinical comparative trials of angiotensin II type 1 (AT1)-receptor blockers.
2001
[Current treatment of diabetic nephropathy in patients with type II diabetes mellitus. Most recent progress].
2001
Drug interactions with irbesartan.
2001
[Choosing the dose of aprovel (irbesartan) in patients with chronic heart insufficiency].
2001
Hypertension and diabetes: the scope of the problem.
2001
Clinical differences among angiotensin II receptor antagonists.
2001
Different types of antagonism by losartan and irbesartan on the effects of angiotensin II and its degradation products in rabbit arteries.
2001 Apr
Irbesartan achieves consistent and effective use over 1 year.
2001 Apr-May
Acute oliguric renal failure associated with angiotensin II receptor antagonists.
2001 Aug
Hemodynamic effects of the angiotensin II receptor antagonist irbesartan in patients with cirrhosis and portal hypertension.
2001 Aug
[Treatment of hypertension in patients with type 2 diabetes. Sartan also protects the kidneys].
2001 Aug 9
Irbesartan slows the development of diabetic nephropathy by up to 70% in hypertensive diabetic patients.
2001 Aug-Sep
Irbesartan prevents the progression of kidney disease or death in patients with type 2 diabetes and high blood pressure.
2001 Aug-Sep
The protective effect of blocking angiotensin in both type I and type II diabetics with nephropathy.
2001 Dec
AT(2) receptor-mediated vasodilation in the heart: effect of myocardial infarction.
2001 Dec
Irbesartan normalises the deficiency in glomerular nephrin expression in a model of diabetes and hypertension.
2001 Jul
New stuff about the diabetic kidney.
2001 Jul-Aug
[Angiotensin II receptor antagonists: different or equivalent?].
2001 Jun 16-23
[Effects of inhibitors of angiotensin-converting enzyme combined with antagonists of angiotensin II receptors on endothelial function in patients with chronic cardiac insufficiency].
2001 Mar-Apr
Drug companies should not have the final say in the design of clinical trials.
2001 Nov
Influence of irbesartan and enalapril on changes of renal function associated with the established phase of l-NAME hypertension.
2001 Nov
Irbesartan, an angiotensin type 1 receptor inhibitor, regulates the vascular oxidative state in patients with coronary artery disease.
2001 Nov 15
[Clinical study of the month. Nephroprotective role of angiotensin II receptor antagonists in type 2 diabetes: results of the IDNT and RENAAL trials].
2001 Oct
Selective angiotensin II receptor antagonism reduces insulin resistance in obese Zucker rats.
2001 Oct
Relation between clinical and therapeutic variables and quality of life in hypertension.
2001 Oct
Comparative effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricaemia and gout.
2001 Oct
Treatment with irbesartan or atenolol improves endothelial function in essential hypertension.
2001 Oct
Angiotensin converting enzyme gene polymorphism predicts blood pressure response to angiotensin II receptor type 1 antagonist treatment in hypertensive patients.
2001 Oct
A clinical trial in type 2 diabetic nephropathy.
2001 Oct
Angiotensin II receptor blockers and nephropathy trials.
2001 Oct
pK(a) determination of angiotensin II receptor antagonists (ARA II) by spectrofluorimetry.
2001 Oct
[Effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes].
2001 Oct 1
Renal protection by angiotensin II receptor antagonists in patients with type 2 diabetes.
2001 Oct 15
[Irbesartan in hypertension. A plus for therapy compliance].
2001 Oct 4
Vasoconstrictor effect of the angiotensin-converting enzyme-resistant, chymase-specific substrate [Pro(11)(D)-Ala(12)] angiotensin I in human dorsal hand veins: in vivo demonstration of non-ace production of angiotensin II in humans.
2001 Oct 9
Adenovirus-mediated overexpression and stimulation of the human angiotensin II type 2 receptor in porcine cardiac fibroblasts does not modulate proliferation, collagen I mRNA expression and ERK1/ERK2 activity, but inhibits protein tyrosine phosphatases.
2001 Sep
Effect of angiotensin II type 1 receptor blockade on experimental hepatic fibrogenesis.
2001 Sep
Differentiation in the angiotensin II receptor 1 blocker class on autonomic function.
2001 Sep
Angiotensin II-induced apoptosis in rat cardiomyocyte culture: a possible role of AT1 and AT2 receptors.
2001 Sep
The pharmacokinetics and pharmacodynamics of irbesartan in heart failure.
2001 Sep
Irbesartan effects on renal function in patients with renal impairment and hypertension: a drug-withdrawal study.
2001 Sep
Angiotensin AT1 receptor antagonist irbesartan decreases lesion size, chemokine expression, and macrophage accumulation in apolipoprotein E-deficient mice.
2001 Sep
Impact of the renin-angiotensin system on cerebral perfusion following subarachnoid haemorrhage in the rat.
2001 Sep 1
The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes.
2001 Sep 20
Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.
2001 Sep 20
Comparative efficacy of olmesartan, losartan, valsartan, and irbesartan in the control of essential hypertension.
2001 Sep-Oct
Vasoconstriction is determined by interstitial rather than circulating angiotensin II.
2002 Jan
Angiotensin peptides modulate bradykinin levels in the interstitium of the dog heart in vivo.
2002 Jan
Patents

Sample Use Guides

Usual Adult Dose for Hypertension
Route of Administration: Oral
In Vitro Use Guide
Curator's Comment:: Contraction responses to increasing concentrations of Ang I (1 nM-1 uM) were evaluated in organ baths in the presence of captopril (10 uM-1 mM) with or without a chymase inhibitor (1 uM soybean trypsin inhibitor), or irbesartan (0.1 nM-uM), in internal mammary arteries from 25 patients undergoing coronary bypass surgery.
0.1 uM irbesartan completely blocked the maximum response to Ang I (from 45.8 +/- 6.7% to 1.9 +/- 1.9%, p < 0.001)
Name Type Language
IRBESARTAN
EMA EPAR   EP   INN   JAN   MART.   MI   ORANGE BOOK   USAN   USP   USP-RS   VANDF   WHO-DD  
INN   USAN  
Official Name English
IRBESARTAN [EP]
Common Name English
1,3-DIAZASPIRO(4.4)NON-1-EN-4-ONE, 2-BUTYL-3-((2'-(1H-TETRAZOL-5-YL)(1,1'-BIPHENYL)-4-YL)METHYL)-
Systematic Name English
IBERSARTAN/HYDROCHLOROTHIAZIDE TEVA COMPONENT IBERSARTAN
Brand Name English
AVALIDE COMPONENT IRBESARTAN
Common Name English
IRBESARTAN [USP MONOGRAPH]
Common Name English
IRBESARTAN COMPONENT OF KARVEZIDE
Brand Name English
IRBESARTAN [INN]
Common Name English
IRBESARTAN [MI]
Common Name English
IBERSARTAN/HYDROCHLOROTHIAZIDE ZENTIVA COMPONENT IBERSARTAN
Brand Name English
IRBESARTAN ZENTIVA
Brand Name English
IRBESARTAN [USP-RS]
Common Name English
IBERSARTAN/HYDROCHLOROTHIAZIDE COMPONENT IBERSARTAN
Brand Name English
SARBEVEL
Brand Name English
IRBESARTAN [VANDF]
Common Name English
IRBESARTAN TEVA
Brand Name English
IRBESARTAN [EMA EPAR]
Common Name English
IRBESARTAN [USAN]
Common Name English
IRBESARTAN COMPONENT OF IFIRMACOMBI
Brand Name English
COAPROVEL COMPONENT IRBESARTAN
Brand Name English
IRBESARTAN BMS
Brand Name English
IRBESARTAN [WHO-DD]
Common Name English
BMS-186295
Code English
IRBESARTAN [USP]
Common Name English
IRBESARTAN [JAN]
Common Name English
IRBESARTAN [EP MONOGRAPH]
Common Name English
IRBESARTAN COMPONENT OF AVALIDE
Common Name English
IBERSARTAN COMPONENT OF IBERSARTAN/HYDROCHLOROTHIAZIDE TEVA
Brand Name English
IFIRMACOMBI COMPONENT IRBESARTAN
Brand Name English
SR 47436
Code English
IRBESARTAN COMPONENT OF COAPROVEL
Brand Name English
SR-47436
Code English
IRBESARTAN [ORANGE BOOK]
Common Name English
AVAPRO
Brand Name English
2-BUTYL-3-(P-(O-1H-TETRAZOL-5-YLPHENYL)BENZYL)-1,3-DIAZASPIRO(4.4)NON-1-EN-4-ONE
Common Name English
NSC-758696
Code English
IRBESARTAN [MART.]
Common Name English
KARVEA
Brand Name English
IBERSARTAN COMPONENT OF IBERSARTAN/HYDROCHLOROTHIAZIDE ZENTIVA
Brand Name English
Classification Tree Code System Code
EMA ASSESSMENT REPORTS IFIRMACOMBI (AUTHORIZED: HYPERTENSION)
Created by admin on Fri Jun 25 21:01:44 UTC 2021 , Edited by admin on Fri Jun 25 21:01:44 UTC 2021
WHO-ATC C09DA04
Created by admin on Fri Jun 25 21:01:44 UTC 2021 , Edited by admin on Fri Jun 25 21:01:44 UTC 2021
EMA ASSESSMENT REPORTS SARBEVEL (AUTHORIZED: HYPERTENSION)
Created by admin on Fri Jun 25 21:01:44 UTC 2021 , Edited by admin on Fri Jun 25 21:01:44 UTC 2021
EMA ASSESSMENT REPORTS IRBESARTAN HYDROCHLOROTHIAZIDE ZENTIVA (AUTHORIZED: HYPERTENSION)
Created by admin on Fri Jun 25 21:01:44 UTC 2021 , Edited by admin on Fri Jun 25 21:01:44 UTC 2021
WHO-ATC C09DB05
Created by admin on Fri Jun 25 21:01:44 UTC 2021 , Edited by admin on Fri Jun 25 21:01:44 UTC 2021
EMA ASSESSMENT REPORTS KARVEA (AUTHORIZED: HYPERTENSION)
Created by admin on Fri Jun 25 21:01:44 UTC 2021 , Edited by admin on Fri Jun 25 21:01:44 UTC 2021
FDA ORPHAN DRUG 496715
Created by admin on Fri Jun 25 21:01:44 UTC 2021 , Edited by admin on Fri Jun 25 21:01:44 UTC 2021
EMA ASSESSMENT REPORTS IRBESARTAN TEVA (AUTHORIZED: HYPERTENSION)
Created by admin on Fri Jun 25 21:01:44 UTC 2021 , Edited by admin on Fri Jun 25 21:01:44 UTC 2021
EMA ASSESSMENT REPORTS IRBESARTAN ZENTIVA (AUTHORIZED: HYPERTENSION)
Created by admin on Fri Jun 25 21:01:44 UTC 2021 , Edited by admin on Fri Jun 25 21:01:44 UTC 2021
EMA ASSESSMENT REPORTS COAPROVEL (AUTHORIZED: HYPERTENSION)
Created by admin on Fri Jun 25 21:01:44 UTC 2021 , Edited by admin on Fri Jun 25 21:01:44 UTC 2021
NCI_THESAURUS C66930
Created by admin on Fri Jun 25 21:01:44 UTC 2021 , Edited by admin on Fri Jun 25 21:01:44 UTC 2021
NDF-RT N0000175561
Created by admin on Fri Jun 25 21:01:44 UTC 2021 , Edited by admin on Fri Jun 25 21:01:44 UTC 2021
NDF-RT N0000000070
Created by admin on Fri Jun 25 21:01:44 UTC 2021 , Edited by admin on Fri Jun 25 21:01:44 UTC 2021
EMA ASSESSMENT REPORTS IRBESARTAN BMS (WITHDRAWN: HYPERTENSION)
Created by admin on Fri Jun 25 21:01:44 UTC 2021 , Edited by admin on Fri Jun 25 21:01:44 UTC 2021
EMA ASSESSMENT REPORTS IRBESARTAN HYDROCHLOROTHIAZIDE BMS (WITHDRAWN: HYPERTENSION)
Created by admin on Fri Jun 25 21:01:44 UTC 2021 , Edited by admin on Fri Jun 25 21:01:44 UTC 2021
EMA ASSESSMENT REPORTS KARVEZIDE (AUTHORIZED: HYPERTENSION)
Created by admin on Fri Jun 25 21:01:44 UTC 2021 , Edited by admin on Fri Jun 25 21:01:44 UTC 2021
WHO-VATC QC09DB05
Created by admin on Fri Jun 25 21:01:44 UTC 2021 , Edited by admin on Fri Jun 25 21:01:44 UTC 2021
WHO-VATC QC09CA04
Created by admin on Fri Jun 25 21:01:44 UTC 2021 , Edited by admin on Fri Jun 25 21:01:44 UTC 2021
WHO-ATC C09CA04
Created by admin on Fri Jun 25 21:01:44 UTC 2021 , Edited by admin on Fri Jun 25 21:01:44 UTC 2021
WHO-VATC QC09DA04
Created by admin on Fri Jun 25 21:01:44 UTC 2021 , Edited by admin on Fri Jun 25 21:01:44 UTC 2021
EMA ASSESSMENT REPORTS IRBESARTAN HYDROCHLOROTHIAZIDE TEVA (AUTHORIZED: HYPERTENSION)
Created by admin on Fri Jun 25 21:01:44 UTC 2021 , Edited by admin on Fri Jun 25 21:01:44 UTC 2021
LIVERTOX 515
Created by admin on Fri Jun 25 21:01:44 UTC 2021 , Edited by admin on Fri Jun 25 21:01:44 UTC 2021
Code System Code Type Description
FDA UNII
J0E2756Z7N
Created by admin on Fri Jun 25 21:01:44 UTC 2021 , Edited by admin on Fri Jun 25 21:01:44 UTC 2021
PRIMARY
DRUG BANK
DB01029
Created by admin on Fri Jun 25 21:01:44 UTC 2021 , Edited by admin on Fri Jun 25 21:01:44 UTC 2021
PRIMARY
WIKIPEDIA
IRBESARTAN
Created by admin on Fri Jun 25 21:01:44 UTC 2021 , Edited by admin on Fri Jun 25 21:01:44 UTC 2021
PRIMARY
IUPHAR
589
Created by admin on Fri Jun 25 21:01:44 UTC 2021 , Edited by admin on Fri Jun 25 21:01:44 UTC 2021
PRIMARY
EPA CompTox
138402-11-6
Created by admin on Fri Jun 25 21:01:44 UTC 2021 , Edited by admin on Fri Jun 25 21:01:44 UTC 2021
PRIMARY
MERCK INDEX
M6397
Created by admin on Fri Jun 25 21:01:44 UTC 2021 , Edited by admin on Fri Jun 25 21:01:44 UTC 2021
PRIMARY Merck Index
PUBCHEM
3749
Created by admin on Fri Jun 25 21:01:44 UTC 2021 , Edited by admin on Fri Jun 25 21:01:44 UTC 2021
PRIMARY
RXCUI
83818
Created by admin on Fri Jun 25 21:01:44 UTC 2021 , Edited by admin on Fri Jun 25 21:01:44 UTC 2021
PRIMARY RxNorm
LACTMED
Irbesartan
Created by admin on Fri Jun 25 21:01:44 UTC 2021 , Edited by admin on Fri Jun 25 21:01:44 UTC 2021
PRIMARY
ChEMBL
CHEMBL1513
Created by admin on Fri Jun 25 21:01:44 UTC 2021 , Edited by admin on Fri Jun 25 21:01:44 UTC 2021
PRIMARY
HSDB
8215
Created by admin on Fri Jun 25 21:01:44 UTC 2021 , Edited by admin on Fri Jun 25 21:01:44 UTC 2021
PRIMARY
USP_CATALOG
1347700
Created by admin on Fri Jun 25 21:01:44 UTC 2021 , Edited by admin on Fri Jun 25 21:01:44 UTC 2021
PRIMARY USP-RS
MESH
C081309
Created by admin on Fri Jun 25 21:01:44 UTC 2021 , Edited by admin on Fri Jun 25 21:01:44 UTC 2021
PRIMARY
INN
7229
Created by admin on Fri Jun 25 21:01:44 UTC 2021 , Edited by admin on Fri Jun 25 21:01:44 UTC 2021
PRIMARY
CAS
138402-11-6
Created by admin on Fri Jun 25 21:01:44 UTC 2021 , Edited by admin on Fri Jun 25 21:01:44 UTC 2021
PRIMARY
EVMPD
SUB08293MIG
Created by admin on Fri Jun 25 21:01:44 UTC 2021 , Edited by admin on Fri Jun 25 21:01:44 UTC 2021
PRIMARY
DRUG CENTRAL
1481
Created by admin on Fri Jun 25 21:01:44 UTC 2021 , Edited by admin on Fri Jun 25 21:01:44 UTC 2021
PRIMARY
NCI_THESAURUS
C29130
Created by admin on Fri Jun 25 21:01:44 UTC 2021 , Edited by admin on Fri Jun 25 21:01:44 UTC 2021
PRIMARY